Passage BIO Reports on Shareholder Vote Matters
Ticker: PASG · Form: 8-K · Filed: May 22, 2024 · CIK: 1787297
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Passage BIO filed an 8-K for a shareholder vote. Details TBD.
AI Summary
Passage BIO, Inc. filed an 8-K on May 21, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain details about specific proposals or outcomes of the vote, but it fulfills the requirement to report such events.
Why It Matters
This filing indicates that Passage BIO held a shareholder vote, a standard corporate governance event. The lack of specific details in this initial report suggests further information might be forthcoming or was previously disclosed.
Risk Assessment
Risk Level: low — This is a routine corporate filing regarding a shareholder vote, with no immediate financial or operational implications disclosed.
Key Players & Entities
- Passage BIO, Inc. (company) — Registrant
- May 21, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Philadelphia, PA (location) — Principal executive offices
FAQ
What specific matters were submitted to a vote of Passage BIO's security holders?
The filing does not specify the exact matters submitted for a vote, only that such matters were presented.
When did the event triggering this 8-K filing occur?
The earliest event reported occurred on May 21, 2024.
What is Passage BIO's state of incorporation?
Passage BIO, Inc. is incorporated in Delaware.
Where are Passage BIO's principal executive offices located?
Passage BIO's principal executive offices are located at One Commerce Square, 2005 Market Street, 39th Floor, Philadelphia, PA 19103.
What is the Commission File Number for Passage BIO?
The Commission File Number for Passage BIO, Inc. is 001-39231.
Filing Stats: 497 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-05-22 16:03:29
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share PASG The Nasdaq S
Filing Documents
- tm2415277d1_8k.htm (8-K) — 36KB
- 0001104659-24-064243.txt ( ) — 207KB
- pasg-20240521.xsd (EX-101.SCH) — 3KB
- pasg-20240521_lab.xml (EX-101.LAB) — 33KB
- pasg-20240521_pre.xml (EX-101.PRE) — 22KB
- tm2415277d1_8k_htm.xml (XML) — 4KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On May 21, 2024, Passage Bio, Inc. (the " Company ") held its 2024 Annual Meeting of Stockholders and the following proposals were adopted: 1. Election of two Class I directors, identified in the table below, each to serve a three-year term, which will expire at the 2027 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until their earlier resignation or removal: Nominees Shares For Shares Withheld Broker Non-Votes William Chou, M.D. 35,909,628 786,951 10,034,554 Derrell Porter, M.D. 27,072,576 9,624,003 10,034,554 2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024: Shares For Shares Against Shares Abstaining Broker Non-Votes 45,565,348 1,104,311 61,474 — 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PASSAGE BIO, INC. Date: May 22, 2024 By: /s/ Kathleen Borthwick Kathleen Borthwick Chief Financial Officer 3